All In Biotech

Drug Trial Radar · NCT07215403

Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Apr 30, 2028

Study completion Nov 1, 2028

Sponsor

Lead sponsor
AskBio IncIndustry
Sponsor type
Industry
Collaborators
Bayer
First posted
Oct 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs treatment. Technical (Stage 0) To test if the new delivery method (prefrontal surgical approach) can consistently deliver AB-1005 to the putamen using MRI monitoring. Technical (Stage 1) To test if the new delivery method (PIA-based infusion) can consistently deliver AB-1005 to the putamen using brain imaging by MRI. Technical (Stage 2) To confirm the new delivery method works without brain imaging by MRI, using standard operating room tools including brain imaging by CT. Safety (Stage 1 and 2) To assess the safety and tolerability of the new delivery method for AB-1005 up to 6 months after surgery

Conditions

  • PARKINSON DISEASE (Disorder)

Interventions

  • Prescriptive Infusion AlgorithmProcedure

    The study intervention is comprised of the neurosurgical procedure and the bilateral intraputaminal delivery of AB-1005.

  • AB-1005Drug

    bilateral intraputaminal delivery of AB-1005

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amount of the putamen covered by the drug at the end of infusion, assessed by MRITime frame: immediately after the intervention/procedure/surgery

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center Neurological Surgery

    Columbus, Ohio

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.